PARIS, October 15, 2025–(BUSINESS WIRE)–Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT“), today provides an update on the ongoing receivership procedure.
Update on the ongoing receivership procedure
Following a call for public tenders (buyers or investors) initiated as part of the receivership opened on July 1, 2025, by the Versailles Economic Court1 (the “Court”), the judiciary administrator had received, on July 31, 2025, one takeover bid within the context of a sales plan (the “Bid”)2, submitted by HOUGOU,…